Group 1 - The company is currently valued at a historical low with a PB of 0.75, indicating strong safety margins [1] - The company has a low interest-bearing debt ratio of 6.3%, the lowest among the top eight state-owned construction enterprises, with cash assets of 39.7 billion yuan [1] - The company has consistently generated positive operating cash flow since its listing, with a total of 13.9 billion yuan in operating and investment cash flow over the past five years [1] Group 2 - The company's caprolactam project is progressing smoothly, benefiting from accelerated import substitution and declining raw material prices, which are expected to significantly enhance profitability [2] - The price of key raw materials for caprolactam, such as butadiene and natural gas, has decreased, leading to an estimated profit increase of 298 million yuan due to lower costs [2] - The company is focusing on a "technology + industry" integrated model, advancing several key pilot projects in new chemical materials and specialty chemicals [2] Group 3 - The domestic construction business is benefiting from accelerated investment in coal chemical projects, while overseas markets remain robust [3] - The company is expected to capture a significant share of the coal chemical investment, with projected annual investments of 117.7 billion yuan in 2025 and 210.4 billion yuan in 2026 [3] - The company signed overseas orders worth 113.3 billion yuan in 2024, continuing to grow from a high base last year, which will drive overall revenue and profit growth [3] Group 4 - The company is projected to achieve net profits of 5.7 billion yuan, 6.3 billion yuan, and 7.2 billion yuan from 2024 to 2026, with corresponding PE ratios of 7.9, 7.2, and 6.3 [4] - The company is recommended for investment due to the acceleration of overseas large orders, benefits from domestic coal chemical investment, and strong cash flow with potential for increased dividends [4]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [4]. Core Views - The company is positioned as a leading comprehensive engineering firm in the chemical construction sector, with a robust growth trajectory supported by a solid order backlog and strategic partnerships [1][4]. - The company aims to leverage its strengths in coal chemical engineering and international markets to enhance its growth potential [2][3]. Summary by Sections Company Overview - The company, originally established as the Third Design Institute of the Ministry of Chemical Industry, has evolved into a leading comprehensive engineering company in China, focusing on technology-driven growth [1][14]. - The major shareholders include China Chemical and Shanxi Coal Group, which provide significant business synergies [1][19]. Business Segments - The company has a strong foothold in chemical engineering, with extensive experience in various sectors, including petrochemicals and environmental management [23]. - The engineering business remains the core revenue and profit source, while the environmental sector is gradually increasing its contribution [27]. Financial Performance - The company has demonstrated steady revenue growth, with a projected CAGR of 14% for revenue and 20% for net profit from 2020 to 2024 [1][37]. - The company reported a significant increase in new orders, with a total of 222.85 billion yuan in new contracts for 2024, reflecting a 24% year-on-year growth [50]. Market Opportunities - The coal chemical industry in Xinjiang is expected to see significant investment, with over 700 billion yuan in proposed projects, providing substantial order opportunities for the company [2]. - The company is actively expanding its international presence, with overseas orders reaching 53 billion yuan in 2023, marking a 177% increase year-on-year [3]. Investment Outlook - The company is expected to benefit from a strong order backlog, with orders amounting to approximately 498 billion yuan, which is 5.6 times its projected revenue for 2024 [50]. - The financial forecasts indicate a net profit of 500 million yuan in 2025 and 651 million yuan in 2026, with corresponding EPS of 0.71 yuan and 0.92 yuan per share [4].